Author

Laura Fasano

Observed name: L. Fasano

Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Florence

Observed institutions: Homi Bhabha National Institute, Kurdistan Regional Government, Rajiv Gandhi Cancer Institute and Research Centre, Azienda Ospedaliero-Universitaria Careggi, Medical University of Lodz, DR. B.R.A. Institute Rotary Cancer Hospital, University of Florence, Cukurova University, All India Institute of Medical Sciences, Assiut University, The University of Texas Health Science Center at Houston

OpenAlex ID: A5102637151

Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia

2023 · Francesco Mannelli, Matteo Piccini, et al. · Haematologica · 6

PDF

A Rare Onset of T-Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations

2024 · Alessandra Mongia, Francesca Romano, et al. · Hematology Reports · 3

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

2022 · Matteo Piccini, Sofia Pilerci, et al. · Blood · 3

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML

2025 · Francesco Mannelli, Matteo Piccini, et al. · Blood Cancer Journal · 2

Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report

2024 · Gaia Ciolli, Andrea Pasquini, et al. · Therapeutic Advances in Hematology · 2

APL-like Subset within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

2023 · Francesca Crupi, Gaia Ciolli, et al. · Blood · 2

PDF

ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting

2023 · Andrea Pasquini, Gaia Ciolli, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Venetoclax and gilteritinib combination for FLT3-mutated relapsed/refractory acute myeloid leukemia: a real-world single-center experience

2026 · Francesca Crupi, Gaia Ciolli, et al. · Haematologica · 1

PDF

APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications

2026 · Francesco Mannelli, Francesca Crupi, et al. · HemaSphere · 1

Caplacizumab in a Case of Very Late Diagnosis of Congenital Thrombotic Thrombocytopenic Purpura

2025 · Elisa Quinti, Laura Fasano, et al. · Research Square

PDF

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting

2024 · Gaia Ciolli, Matteo Piccini, et al. · Haematologica

PDF

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA-Mutated Acute Myeloid Leukemia

2023 · Francesco Mannelli, Matteo Piccini, et al. · Blood

PDF

POSTER: ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting

2023 · Andrea Pasquini, Gaia Ciolli, et al. · Clinical Lymphoma Myeloma & Leukemia

AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting

2023 · Matteo Piccini, Giacomo Gianfaldoni, et al. · Clinical Lymphoma Myeloma & Leukemia

AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications

2023 · Gaia Ciolli, Francesca Crupi, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications

2023 · Gaia Ciolli, Francesca Crupi, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting

2023 · Matteo Piccini, Giacomo Gianfaldoni, et al. · Clinical Lymphoma Myeloma & Leukemia

P529: the Effect of Age and Treatment on the Predictive Value of Measurable Residual Disease: Implications for the Clinical Management of Adult Patients With Acute Myeloid Leukemia

2023 · Francesco Mannelli, Matteo Piccini, et al. · HemaSphere

Works count: 21

Citation count: 22

H-index: 3

I10-index: